BBH ETF News
NASDAQ: BBHVanEckHealthETFUSD
240.47+6.66 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BBH news summary
We found 2 recent headlines mentioning VanEck Biotech (BBH): 1 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, BBH is up 2.85% at $240.47. The most recent story, "Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma", was published by Nasdaq on Oct 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BBH headlines
- Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting PharmaKey PointsThe VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%.NasdaqXPH, BBH
- Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateBiotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.NasdaqAMGN, ILMN, MRNA, HALO